Shilpa Medicare Ltd Falls to 52-Week Low of Rs.264 Amid Continued Downtrend

Stock Price Movement and Market Context

On the day the new low was recorded, Shilpa Medicare’s stock fell by 2.18%, underperforming its sector by 2.02%. The intraday low of Rs.264 represented a 2.46% drop from the previous close. This decline is part of a broader downtrend, with the stock experiencing losses for 11 consecutive trading sessions, resulting in a cumulative return of -16.8% over this period.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. This contrasts with the broader market, where the Sensex opened flat but later declined by 300.33 points (-0.33%) to 82,035.61. Notably, the Sensex itself is trading below its 50-day moving average, although its 50DMA remains above the 200DMA, indicating mixed technical signals at the index level.

Long-Term Performance and Valuation Metrics

Over the last 12 months, Shilpa Medicare’s stock has delivered a negative return of -35.01%, significantly underperforming the Sensex, which posted a positive return of 7.21% during the same period. The stock’s 52-week high was Rs.501.6, highlighting the extent of the decline from its peak.

The company’s market capitalisation is graded at 3, reflecting its mid-tier size within the Pharmaceuticals & Biotechnology sector. Its Mojo Score stands at 29.0, with a recent downgrade from a ‘Sell’ to a ‘Strong Sell’ rating on 19 Nov 2025, underscoring concerns about its fundamental strength and market outlook.

Fundamental Analysis and Financial Trends

Shilpa Medicare’s long-term fundamental strength remains subdued, with an average Return on Capital Employed (ROCE) of 4.57%. This figure is modest relative to industry standards and indicates limited efficiency in generating returns from capital investments. Over the past five years, the company’s net sales have grown at an annualised rate of 6.95%, while operating profit has increased at a slower pace of 3.16%, reflecting constrained profitability expansion.

Despite these challenges, the company has reported positive results for nine consecutive quarters, with a half-year ROCE peaking at 8.57%. The operating profit to interest coverage ratio reached a high of 6.91 times, signalling adequate ability to service debt obligations. Additionally, the dividend payout ratio (DPR) for the year hit 14.01%, indicating a moderate return of earnings to shareholders.

Valuation and Institutional Participation

From a valuation perspective, Shilpa Medicare presents an attractive profile with an enterprise value to capital employed ratio of 1.9, suggesting the stock is trading at a discount relative to its peers’ historical averages. The company’s profits have risen sharply by 194.5% over the past year, despite the stock’s negative price performance. This divergence is reflected in a low PEG ratio of 0.2, which measures price relative to earnings growth.

Institutional investors have increased their stake by 0.71% in the previous quarter, now collectively holding 19.3% of the company’s shares. This uptick in institutional participation indicates a degree of confidence in the company’s fundamentals from investors with extensive analytical resources.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Shilpa Medicare’s performance has lagged behind broader market indices. While the BSE500 index generated returns of 6.03% over the last year, Shilpa Medicare’s stock declined by 35.01%. This underperformance is notable given the sector’s generally resilient profile amid market fluctuations.

Other indices, such as NIFTY REALTY, also hit new 52-week lows on the same day, reflecting sector-specific pressures and broader market volatility. The Sensex’s technical positioning below its 50-day moving average adds to the cautious environment for stocks like Shilpa Medicare.

Summary of Key Metrics

To summarise, Shilpa Medicare Ltd’s stock has reached a new 52-week low of Rs.264 after a sustained period of decline. The stock’s current Mojo Grade is ‘Strong Sell’, downgraded from ‘Sell’ in November 2025, with a Mojo Score of 29.0. The company’s fundamental indicators show modest growth and profitability, with average ROCE at 4.57% and slow operating profit expansion. Despite positive quarterly results and increased institutional holdings, the stock’s valuation and price performance remain subdued relative to peers and market benchmarks.

These factors collectively explain the stock’s recent price weakness and its position at a significant technical support level.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →